Ruthenium-Cathepsin Inhibitor Conjugates for Green Light-Activated Photodynamic Therapy and Photochemotherapy
- 15 April 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 63 (17) , 7973-7983
Abstract
Dysregulated cathepsin activity is linked to various human diseases including metabolic disorders, autoimmune conditions, and cancer. Given the overexpression of cathepsin in the tumor microenvironment, cathepsin inhibitors are promising pharmacological agents and drug delivery vehicles for cancer treatment. In this study, we describe the synthesis and photochemical and biological assessment of a dual-action agent based on ruthenium that is conjugated with a cathepsin inhibitor, designed for both photodynamic therapy (PDT) and photochemotherapy (PCT). The ruthenium-cathepsin inhibitor conjugate was synthesized through an oxime click reaction, combining a pan-cathepsin inhibitor based on E64d with the Ru(II) PCT/PDT fragment [Ru(dqpy)(dppn)], where dqpy = 2,6-di(quinoline-2-yl)pyridine and dppn = benzo[i]dipyrido[3,2-a:2',3'-c]phenazine. Photochemical investigations validated the conjugate's ability to release a triazole-containing cathepsin inhibitor for PCT and to generate singlet oxygen for PDT upon exposure to green light. Inhibition studies demonstrated the conjugate's potent and irreversible inactivation of purified and intracellular cysteine cathepsins. Two Ru(II) PCT/PDT agents based on the [Ru(dqpy)(dppn)] moiety were evaluated for photoinduced cytotoxicity in 4T1 murine triple-negative breast cancer cells, L929 fibroblasts, and M0, M1, and M2 macrophages. The cathepsin inhibitor conjugate displayed notable selectivity for inducing cell death under irradiation compared to dark conditions, mitigating toxicity in the dark observed with the triazole control complex [Ru(dqpy)(dppn)(MeTz)]2+ (MeTz = 1-methyl-1H-1,2,4-triazole). Notably, our lead complex is among a limited number of dual PCT/PDT agents activated with green light.Keywords
Funding Information
- Division of Chemistry (CHE 2102508)
- NIH Office of the Director (S10OD028488)
- Wayne State University
- National Institute of General Medical Sciences (R01 GM098285-07S1, T32GM142519)
This publication has 87 references indexed in Scilit:
- A Near‐Infrared Light‐Activated Photocage Based on a Ruthenium Complex for Cancer PhototherapyAngewandte Chemie International Edition, 2023
- Towards Selective Delivery of a Ruthenium(II) Polypyridyl Complex‐Containing Bombesin Conjugate into Cancer CellsChemBioChem, 2023
- Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor‐Associated MacrophagesChemistry – A European Journal, 2022
- Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor SunitinibChemistry & Biodiversity, 2018
- Macrophage plasticity, polarization, and function in health and diseaseJournal of Cellular Physiology, 2018
- A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer CellsAngewandte Chemie International Edition, 2017
- Towards Selective Light‐Activated RuII‐Based Prodrug CandidatesEuropean Journal of Inorganic Chemistry, 2015
- Immuno‐Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer AgentsAngewandte Chemie International Edition, 2014
- Oxime Ligation: A Chemoselective Click‐Type Reaction for Accessing Multifunctional Biomolecular ConstructsChemistry – A European Journal, 2013
- Ruthenium(II)–Arene Complexes with Strong Fluorescence: Insight into the Underlying MechanismChemistry – A European Journal, 2012